AllAnalyst Report
logoArgusJanuary 20, 2021

Gilead Sciences, Inc.: Looking for more favorable entry point

Symbols
GILD
Sector(s)
Healthcare
Rating
Current Price
$65.77
Price Target
$NaN
Earnings Estimate
Summary

Gilead Sciences is a California-based biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 11,800 employees.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free

Analyst Profile

Jasper Hellweg

Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.